Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35605176/
1 Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia. 2 Moores Cancer Center, University of California, San Diego, California, United States. 3 University of Cologne,...
Conclusion: No new safety signals were identified. Sustained survival, uMRD benefits and durable responses support 2-year fixed-duration venetoclax-rituximab treatment in R/R CLL.
Impact of the MRD status in AML patients undergoing allogeneic stem cell transplantation in first vs second remission
Research Article | Madlen Jentzsch, Lara Bischof, Donata Backhaus, Dominic Brauer, Julia Schulz, Georg-Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Uwe Platzbecker, Sebastian Schwind; Impact of the MRD status in AML...
Conclusion: In the clinically highly relevant group of ELN2017 intermediate risk individuals, the MRD status provided the highest prognostic value with very dismal outcomes of patients transplanted in MRDpos second remission. The adverse outcomes of MRDpos patients and individuals transplanted in second remission should be considered when...
Drug resistance and minimal residual disease in multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35582527/
Great progress has been made in improving survival in multiple myeloma (MM) patients over the last 30 years. New drugs have been introduced and complete responses are frequently seen. However,...
Relevance: Sustained MRD negativity is related to prolonged survival, and it is evaluated in all recent clinical trials as a surrogate of drug efficacy.
Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35582835/
Measurement of minimal residual disease (MRD) by next-generation flow cytometry (NGF) is an important tool to define deep responses in multiple myeloma (MM). However, little is known about the value...
Conclusion: We show that combining NGF with imaging is helpful particularly in patients with heavily pretreated MM, and that MRD-based consolidation could lead to improved PFS.
Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
Source : https://www.isct-cytotherapy.org/article/S1465-3249(22)00078-0/fulltext
An intensified conditioning regimen incorporating medium-dose etoposide (VP16) is an option for patients with acute lymphoblastic leukemia (ALL). However, the prognostic impacts of the addition of VP16 to cyclophosphamide (CY)...
Conclusions: This study demonstrated the benefits of the addition of VP16 in Ph ALL patients, especially those with positive MRD status. VP16/CY/TBI could be a potential strategy to overcome the survival risk of MRD positivity.